In prostate, c-myc is often amplified in advanced cancer specimens54, so that targeted inhibition of its overexpression has been demonstrated as a promising therapeutic strategy for clinical management of prostate cancer.55 Moreover, therapeutic use of c-myc antisense renders hormone-refractory prostate cancers responsive to chemotherapy in the preclinical model.56 This evidence concerns the gene MYC and prostate carcinoma.